ID   SKW 6.4
AC   CVCL_3796
SY   SKW6.4; Skw6.4; SKW 6-4; SKW6-Cl4; SKW6-CL4; SKW6 clone 4; SKW6-4
DR   BTO; BTO:0001936
DR   CLO; CLO_0009067
DR   ATCC; TIB-215
DR   ChEMBL-Cells; CHEMBL3307453
DR   ChEMBL-Targets; CHEMBL614928
DR   Lonza; 83
DR   PubChem_Cell_line; CVCL_3796
DR   Wikidata; Q54954813
RX   Patent=US4730036;
RX   PubMed=305004;
RX   PubMed=6339249;
RX   PubMed=6605913;
RX   PubMed=8509142;
RX   PubMed=19220422;
CC   Problematic cell line: Contaminated. Shown to be a WIL2-A3 derivative (ICLAC). Based on the STR profile. The exact WIL2 derivative has been arbitrarily chosen to be WIL2-A3 because this cell line was used in the lab where SKW 6.4 was derived (PubMed=305004). Originally thought to originate from the Daudi cell line.
CC   Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00617.
CC   Population: Caucasian.
CC   Characteristics: Produces and secretes IgM.
CC   Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly59_Thr125del (c.175_375del199); Zygosity=Heterozygous (PubMed=19220422).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Spleen; UBERON=UBERON_0002106.
ST   Source(s): ATCC
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 11,12
ST   D5S818: 12,13
ST   D7S820: 9,11
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 17,20
DI   NCIt; C97074; Hereditary spherocytosis
DI   ORDO; Orphanet_822; Hereditary spherocytosis
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   5Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 18
RX   Patent=US4730036;
RA   Ralph P., Welte K.;
RT   "Purifications of B-cell inducing factor (BIF) and B-cell growth
RT   factor (BGF).";
RL   Patent number US4730036, 08-Mar-1988.
RX   PubMed=305004; DOI=10.1038/271756a0;
RA   Kishimoto T., Hirano T., Kuritani T., Yamamura Y., Ralph P.,
RA   Good R.A.;
RT   "Induction of IgG production in human B lymphoblastoid cell lines with
RT   normal human T cells.";
RL   Nature 271:756-758(1978).
RX   PubMed=6339249; DOI=10.1002/eji.1830130108;
RA   Saiki O., Ralph P.;
RT   "Clonal differences in response to T cell replacing factor (TRF) for
RT   IgM secretion and TRF receptors in a human B lymphoblast cell line.";
RL   Eur. J. Immunol. 13:31-34(1983).
RX   PubMed=6605913; DOI=10.1016/0165-2478(83)90049-4;
RA   Ralph P., Saiki O., Maurer D.H., Welte K.;
RT   "IgM and IgG secretion in human B-cell lines regulated by
RT   B-cell-inducing factors (BIF) and phorbol ester.";
RL   Immunol. Lett. 7:17-23(1983).
RX   PubMed=8509142;
RA   Cheng P.P.-J., Sreedharan S.P., Kishiyama J.L., Goetzl E.J.;
RT   "The SKW 6.4 line of human B lymphocytes specifically binds and
RT   responds to vasoactive intestinal peptide.";
RL   Immunology 79:64-68(1993).
RX   PubMed=19220422; DOI=10.1111/j.1600-0609.2009.01211.x;
RA   Kamihira S., Terada C., Sasaki D., Yanagihara K., Tsukasaki K.,
RA   Hasegawa H., Yamada Y.;
RT   "Aberrant p53 protein expression and function in a panel of
RT   hematopoietic cell lines with different p53 mutations.";
RL   Eur. J. Haematol. 82:301-307(2009).